This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Faruqi & Faruqi, LLP Files Securities Class Action Suit Against China Medical Technologies, Inc. And Certain Of Its Executives

NEW YORK, Feb. 3, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP today announced that it has filed a securities class action lawsuit against China Medical Technologies, Inc. ("China Medical" or the "Company") (NASDAQ: CMED) and certain of its senior executives.  The action (No. 12-CIV-0882), filed in the United States District Court for the Southern District of New York, asserts claims under the Securities Exchange Act of 1934 ("Exchange Act") on behalf of all persons who purchased or otherwise acquired CMED's American Depositary Shares ("ADS") during the expanded period between February 7, 2007 and December 12, 2011, inclusive (the "Class Period").   

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

A copy of the complaint can be viewed on the firm's website at www.faruqilaw.com/CMED.

China Medical and certain of its senior executives are charged with issuing a series of materially false and misleading statements in violation of Section 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder.  Specifically, defendants misstated and failed to disclose that the Company engaged in suspicious and improper related-party transactions and misstated its receivables in order to artificially inflate sales and net income.  As a result of defendants' false and misleading statements and material omissions, China Medical ADS traded at artificially inflated prices during the Class Period, reaching a high of $57.50 per share on February 28, 2008.

On December 6, 2011, the Glaucus Research Group published a report that revealed that China Medical's Chief Executive Officer engaged in a related party transaction with the Company pursuant to which the Company improperly funneled approximately $20 million to the Company's Chief Executive Officer.  The report also concluded that the Company's profits, revenue and net income were severely inflated.  On this news, China Medical's shares declined nearly 24% on unusually high trading volume.  Moreover, on December 13, 2011, China Medical further disclosed that the Company intended to restructure its debt to improve its balance sheets.  This news caused China Medical's shares to decline an additional 13% to close at $2.87 per share, on unusually high trading volume.

The true facts, which were known by the defendants but concealed from the investing public during the Class Period, were as follows:  (1) several China Medical acquisitions during the Class Period were the result of suspicious and/or improper related party transactions with third-party sellers connected to the Company; (2) the Company significantly overpaid for at least one acquisition to the detriment of Company shareholders and to the benefit of China Medical's Chairman of the Board and Chief Executive Officer, defendant Xiaodong Wu; (3) the Company overstated accounts receivable in order to inflate reported sales, profit margins and net income; and (4) as a result of the foregoing, the Company's financial performance, expected earnings and business prospects were false and misleading and lacked a reasonable basis when made.  As a result, the Complaint alleges that China Medical violated provisions of the Exchange Act during the Class Period by issuing false and misleading press releases, financial statements, filings with the Securities and Exchange Commission and statements during investor conference calls. 

Plaintiff now seeks to recover damages on behalf of himself and all other investors who purchased or acquired China Medical ADS during the Class Period, excluding defendants and their affiliates.  Plaintiff is represented by Faruqi & Faruqi, LLP, a national securities law firm with extensive experience in prosecuting class actions involving corporate fraud. 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs